If a medication is available in the US but not in your country, read When conventional access fails.

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team. The United Kingdom holds a unique position in the global specialty-drug landscape. The MHRA is one of the most respected medicines regulators in the world; NICE sets a global benchmark for health-technology appraisal; and yet UK patients regularly face access gaps that the cross-border Specials pathway exists to bridge. Here is how it actually works.

Why UK patients face an access gap in the first place

The United Kingdom has a sophisticated and tightly regulated medicines market. The Medicines and Healthcare products Regulatory Agency (MHRA) authorises medicines for the Great Britain market. The National Institute for Health and Care Excellence (NICE) appraises whether the National Health Service (NHS) will fund new medicines on cost-effectiveness grounds. NHS England Specialised Commissioning sets the budget and the clinical commissioning policy for high-cost specialty therapies in England, with parallel arrangements through NHS Scotland (advised by the Scottish Medicines Consortium), NHS Wales (advised by the All Wales Medicines Strategy Group), and the Health and Social Care system in Northern Ireland.

Despite this depth of infrastructure, UK patients consistently encounter four access gaps that drive cross-border cases.

Gap one: NICE has not yet recommended the medicine. NICE technology appraisal can lag US Food and Drug Administration approval by 12 to 36 months, and sometimes considerably longer. During the appraisal interval, the medicine is not routinely funded by the NHS even when MHRA has granted a marketing authorisation. Recent examples include the anti-amyloid Alzheimer's antibodies, several CAR-T cell therapies, and a range of gene therapies for rare diseases.

Gap two: NICE has issued a not-recommended decision or a restrictive recommendation. Lecanemab (Leqembi) and donanemab are recent and prominent examples. NICE issued draft guidance in 2024 that did not recommend lecanemab for routine NHS funding in early Alzheimer's disease, citing cost-effectiveness concerns despite MHRA marketing authorisation. Patients whose neurologist has identified them as suitable candidates have no NHS route and pursue private supply.

Gap three: The medicine is not licensed in the UK at all. Some US-approved medicines never apply for UK marketing authorisation, often because the patient population is small (orphan diseases, certain rare oncology indications) or because the manufacturer has chosen a different European market-entry strategy post-Brexit. For these medicines the Specials Licence pathway, set out in regulations 167 and 168 of the Human Medicines Regulations 2012, is the lawful import mechanism.

Gap four: NHS waiting lists, regional postcode variation, and stocking gaps. Even when a medicine is NICE-recommended, regional commissioning variation, hospital formulary inclusion timelines, and NHS waiting list pressure can delay therapy initiation by months. Private patients and self-funders pursue alternative supply routes during the wait.

Each of these gaps has the same regulatory remedy: a UK-licensed prescriber, the Specials Licence framework, and a licensed wholesale dealer or Specials-licensed manufacturer who can lawfully import the medicine for the specific patient.

The MHRA Specials Licence pathway

The Specials regime, properly called specials or unlicensed medicines, is the UK's long-established mechanism for supplying a medicine that does not hold a UK marketing authorisation when no licensed equivalent meets the patient's clinical need. The legal framework sits in the Human Medicines Regulations 2012 (S.I. 2012/1916), with the core provisions at regulations 167 (exemptions for supply in response to a special clinical need) and 168 (manufacture and assembly), and the MHRA enforces compliance.

The architecture works through four elements. First, a UK-registered prescriber, typically a consultant working under their General Medical Council registration and within their scope of practice, makes a clinical decision that the unlicensed medicine is needed to meet the special clinical needs of the patient. The prescriber takes full clinical responsibility. Second, the medicine is supplied through a Specials Licence holder. Specials Licences are issued by the MHRA either as a Manufacturer's Specials Licence (for UK manufacture or assembly) or as a Wholesale Dealer's Licence with the appropriate authorisation to import an unlicensed medicine. Third, the supply is for a named individual patient against a valid UK prescription, not stock supply, and the supplier notifies the MHRA of each import of an unlicensed medicine within prescribed timelines. Fourth, the dispensing pharmacy, which may be the Specials Licence holder itself or a separate registered pharmacy, releases the medicine to the patient or the administering clinical facility under chain-of-custody documentation.

The clinical justification is rarely a contested point in the UK system because the special clinical need test is a clinical judgment that rests with the prescribing consultant. The operational complexity sits in the supply chain: identifying the correct Specials Licence holder, securing the medicine from the US manufacturer or an authorised distributor, validating cold-chain handling where applicable, and completing MHRA import notification.

For US-sourced medicines specifically, the supply chain typically routes US manufacturer or US authorised distributor, to a UK Wholesale Dealer's Licence holder with import authorisation, to the UK Specials-licensed dispensing pharmacy, to the patient or the administering centre. Reserve Meds orchestrates the US-side sourcing and works alongside a UK-licensed Specials wholesaler or specialty pharmacy that holds the appropriate authorisations.

The Early Access to Medicines Scheme (EAMS)

The Early Access to Medicines Scheme, run by the MHRA, is a parallel route that operates upstream of marketing authorisation. EAMS allows patients with life-threatening or seriously debilitating conditions to access a medicine that has been granted a Promising Innovative Medicine designation and a positive scientific opinion before formal MHRA marketing authorisation. EAMS supply is typically free of charge to the patient because the manufacturer covers the cost, and the scheme operates through participating NHS centres. EAMS is the right route for medicines that are pre-licence in the UK but where the manufacturer has chosen to participate; it is not a substitute for the Specials route, which handles medicines that are post-US-approval but not in scope of an EAMS programme, or where EAMS supply is not available in the patient's region.

NICE technology appraisal and what a not-recommended decision means

A NICE Technology Appraisal is a structured cost-effectiveness review that determines whether the NHS will fund a new medicine within its statutory remit. A positive recommendation creates a funding mandate for NHS England within 90 days. A not-recommended decision, or an optimised recommendation that excludes the patient's specific indication or subgroup, means the NHS will not routinely fund the medicine for that use.

A not-recommended decision does not affect MHRA marketing authorisation, and it does not prohibit private supply. UK patients in this position have three routes: pay privately for the medicine through a UK private prescription dispensed by a Specials-licensed or fully-licensed UK pharmacy, access the medicine through a manufacturer compassionate use or expanded access programme where available, or pursue the Specials cross-border route when UK private supply is not feasible (often the case for medicines without UK marketing authorisation).

Several oncology medicines also access NHS funding through the Cancer Drugs Fund, a managed-access mechanism that lets NHS England fund a medicine while additional evidence is collected. Cancer Drugs Fund inclusion is decided alongside the NICE appraisal and follows a similar process.

NHS England Specialised Commissioning and the regional picture

For specialty therapies in England, NHS England Specialised Commissioning is the funder, not the local Integrated Care Board. Specialised Commissioning operates regional teams and a national policy framework, with clinical commissioning policies and a managed-access process that links to NICE. For Scotland, the Scottish Medicines Consortium issues its own advice and NHS Scotland health boards commission accordingly. In Wales, the All Wales Medicines Strategy Group advises on medicines not covered by NICE, and NHS Wales health boards commission. In Northern Ireland, the Health and Social Care Board takes account of NICE and SMC guidance.

Regional variation, often described as the postcode lottery, remains a real feature. A NICE-recommended medicine should be funded uniformly, but waiting time, hospital formulary timing, and access to the appropriate prescribing centre vary materially across the four UK nations and within England's regions. Private patients and self-funders pursue specialty supply routes during these gaps.

Where US-sourced specialty medicines get dispensed in the UK

UK dispensing for cross-border specialty medicines runs through three operational channels.

The first channel is a Specials-licensed wholesaler or specialty pharmacy, which holds the MHRA wholesale dealer authorisation that permits import of unlicensed medicines. These organisations are the regulatory backbone of the Specials supply chain. Established UK names that operate in this space include Lloyds Clinical Homecare (a long-standing clinical homecare provider with a national footprint and extensive specialty pharmacy infrastructure), Sciensus (one of the largest specialty pharmacy and homecare providers in the UK, with significant biologics and oncology experience), Polar Speed Distribution (a UK-based specialist medicines distributor), and a number of independent Specials-focused wholesalers and pharmacies. Reserve Meds does not endorse any single provider; the right operational partner depends on the medicine, the route of administration, the patient location, and the prescribing centre.

The second channel is a private hospital pharmacy attached to a UK private hospital. The leading UK private hospitals with established specialty drug handling and the ability to administer infused therapies on site include The London Clinic in Marylebone, Cromwell Hospital in Kensington (Bupa Cromwell), HCA Healthcare UK at University College Hospital (the private patient unit attached to UCLH), The Wellington Hospital in St John's Wood, The Princess Grace Hospital, The Royal Marsden Private Care (the private extension of the Royal Marsden NHS Foundation Trust), and the Harley Street Clinic. For oncology and rare-disease cases the Royal Marsden Private Care, HCA UK at UCH, and The London Clinic handle the most complex private specialty therapy in the country.

The third channel is an NHS hospital pharmacy operating under a Specials Licence arrangement when the medicine is being supplied to an NHS patient through the Specials route or through an EAMS programme. NHS Trust pharmacies in major tertiary centres (Royal Free London, Guy's and St Thomas', King's College Hospital, the Royal Marsden, University College London Hospitals, Addenbrooke's in Cambridge, the Christie in Manchester, the Western General in Edinburgh, and others) handle specials imports as part of their standard pharmaceutical practice.

For cold-chain biologics and cell and gene therapies, the dispensing facility must maintain validated 2 to 8 degrees Celsius storage with continuous monitoring, and for cryopreserved cell therapies the facility must hold the appropriate JACIE-accredited cell therapy infrastructure. The UK has approximately ten JACIE-accredited adult and paediatric cell therapy centres delivering CAR-T and related cell therapies, including King's College Hospital, the Royal Marsden, UCLH, the Christie, Newcastle, Manchester Royal Infirmary, the Queen Elizabeth Hospital Birmingham, and Glasgow's Beatson West of Scotland Cancer Centre.

Real cost picture: what UK patients actually pay

Costs vary widely by medicine. To set context, the GBP figures below convert from US wholesale acquisition cost (WAC) at approximately 0.79 GBP to 1 USD as of mid-2026, before adding UK supply chain costs, import documentation handling, and the Reserve Meds concierge fee. Private UK pharmacy supply may add its own dispensing fee and clinical service margin on top of the imported product cost.

For a major specialty oral oncology medicine such as an ALK inhibitor or BTK inhibitor, a 30-day supply at US WAC equivalents typically lands in the GBP 4,700 to 9,500 monthly range for the medicine alone, plus international logistics (GBP 320 to 1,200 depending on whether cold chain is required), plus UK regulatory and import documentation fees, plus our concierge fee. Private UK supply of NICE-positive medicines from a UK-licensed pharmacy may run at a similar headline range with a different fee mix.

For a biologic such as Dupixent (dupilumab) at the standard adult atopic dermatitis dose, US WAC is approximately USD 3,993 per 300 mg pen carton, and annual WAC for the typical 26-dose schedule converts to roughly GBP 29,000 to 34,000 at current exchange rates, before UK supply and fees.

For a CAR-T cell therapy with a US list price in the USD 425,000 to 525,000 range, GBP equivalents run roughly 335,000 to 415,000 for the product alone, with substantial additional cost for the apheresis-to-infusion logistics chain and the cell therapy centre's procedural costs.

For a gene therapy such as Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy, the US list price is approximately USD 2.1 million and the medicine has been subject to a Patient Access Scheme in the UK; private supply costs sit in a similar order of magnitude.

The Reserve Meds waitlist form generates an indicative range first, then a transparent firm quote with each line item separated. Nothing is bundled or hidden.

Typical timeline for a UK Specials case

From the family side, the indicative timeline for a routine Specials case runs approximately as follows. Day 0 is the prescribing consultant's decision and prescription. Day 1 to 3 is the documentation set assembly: the prescription, the special clinical need note, prescriber GMC and licence verification, and the destination dispensing facility confirmation. Day 3 to 10 is the US-side sourcing and the international shipment. Day 10 to 14 is UK customs clearance, MHRA import notification, and arrival at the dispensing facility. Day 14 to 21 is the dispensing pharmacy's release and the start of therapy.

For pre-licence medicines accessed through EAMS, the timeline depends on the manufacturer's EAMS programme and the participating NHS centre's onboarding cadence; this is generally a slower process than a direct Specials import because EAMS supply is centrally orchestrated by the manufacturer.

For cold-chain biologics, the operational complexity of the cold chain adds 1 to 3 days versus an ambient small molecule. For cell and gene therapies, the timeline is dominated by the cell collection (apheresis), manufacture, and release schedule, which is intrinsic to the therapy and not specific to the cross-border route.

What your physician needs to provide

For a UK consultant prescribing a specials import, the documentation set is shorter and more clinically focused than the equivalent in many other jurisdictions, because the regulatory mechanism rests on the prescriber's clinical responsibility rather than on a pre-authorisation gate.

The core elements are a valid UK private prescription on consultant headed paper or through the appropriate electronic prescribing system, a clear identification of the medicine (brand name, generic name, strength, quantity, dosing schedule, anticipated duration), the special clinical need note that explains why no licensed UK alternative meets the patient's need (typically a short paragraph in the clinical record or a covering letter), confirmation of the prescriber's General Medical Council registration and licence to practise, identification of the destination dispensing facility and its Specials Licence or pharmacy registration, and any indication-specific clinical documentation that the dispensing pharmacy or specialty centre requires.

For controlled drugs (which Reserve Meds does not handle in any case), additional Home Office controlled drug licence considerations apply. For unlicensed medicines that are not controlled drugs, the GMC's prescribing guidance for unlicensed medicines and the General Pharmaceutical Council standards on dispensing unlicensed medicines set the professional framework.

Patient Group Direction and other supply mechanisms

A Patient Group Direction is a written instruction that allows specified healthcare professionals (typically nurses, pharmacists, or paramedics) to supply or administer a named medicine to a defined patient group without an individual prescription. Patient Group Directions are widely used in NHS settings for vaccination, contraception, and certain chronic disease management. They are not the primary mechanism for specialty unlicensed medicines; for those the Specials route under a consultant's prescription remains the standard.

The Yellow Card scheme is the MHRA's pharmacovigilance reporting system. Suspected adverse drug reactions from any medicine, including unlicensed Specials, should be reported through the Yellow Card scheme by the prescriber, the dispensing pharmacy, or the patient. Reserve Meds coordinates the pharmacovigilance reporting chain back to the US manufacturer as part of standard cross-border pharmacy practice.

Common UK-specific questions

Will the NHS pay for this?

If NICE has recommended the medicine for the patient's specific indication and population, the NHS funds it through the standard commissioning route, typically NHS England Specialised Commissioning for high-cost specialty therapies. If NICE has not yet appraised the medicine, has issued a not-recommended decision, or has issued an optimised recommendation that does not cover the patient's situation, the NHS does not routinely fund and the patient pursues private supply or an Individual Funding Request to NHS England, which is a high-bar exceptionality test that succeeds only in genuinely exceptional cases. The Cancer Drugs Fund provides managed access for selected oncology medicines.

What about private medical insurance?

Major UK private medical insurers (Bupa, AXA Health, Vitality, Aviva, WPA, Healix) handle specialty drug claims case by case. Cover typically requires the medicine to be MHRA-licensed and used on-label for an insured condition; off-label use and unlicensed Specials are commonly excluded or require pre-authorisation. Cash-pay is the default posture for Reserve Meds patients, with insurance reimbursement pursued separately by the patient where applicable. We provide documentation that supports a claim; we do not process claims directly.

What about EU-licensed medicines post-Brexit?

Following the UK's exit from the European Union, the MHRA operates independently. EU-licensed medicines are not automatically licensed in Great Britain, although the MHRA has historically used reliance routes for EU decisions. For Northern Ireland, the Windsor Framework and the previous Northern Ireland Protocol create distinct rules; Northern Ireland patients often access EMA-licensed medicines through routes not available in Great Britain. Reserve Meds focuses on US-sourced supply; medicines that are licensed in the EU but not in the UK can also be imported under the Specials framework, but the supply chain economics may favour EU sourcing in those cases.

Can I receive the medicine at home or do I need a hospital?

For oral medicines and self-administered subcutaneous injectables, the dispensing pharmacy can release the medicine to the patient after the appropriate clinical onboarding. UK clinical homecare providers (Sciensus, Lloyds Clinical Homecare, Healthnet Homecare, HAH, BioScript) deliver and administer many biologics in the patient's home under nursing supervision. For infused medicines, including chemotherapies and most monoclonal antibodies, infusion takes place in a hospital outpatient infusion suite or a homecare-administered setting depending on the medicine and the patient's clinical profile. For cell and gene therapies, infusion or injection takes place in an accredited specialty centre.

What about controlled drugs and unlicensed cannabis-based medicines?

Reserve Meds does not handle controlled drugs (any UK Schedule 1 to 5 medicine under the Misuse of Drugs Regulations 2001) and we do not handle cannabis-based products for medicinal use. Those imports require Home Office licensing and a separate specialist supply chain.

What about paediatric patients?

The Specials framework applies the same way for paediatric patients, with the additional consideration that the prescribing consultant is typically a paediatric subspecialist (paediatric oncology, paediatric neurology, paediatric rheumatology, and so on). UK paediatric specialty hospitals including Great Ormond Street Hospital, Birmingham Children's Hospital, Manchester Children's, Royal Hospital for Children Glasgow, and Sheffield Children's handle Specials imports as routine pharmacy practice. Paediatric weight-banded dosing and presentation selection are typical operational considerations.

What about Northern Ireland, Scotland, and Wales specifically?

Each devolved nation has its own NHS commissioner but the MHRA Specials framework operates across the whole UK. Scotland's Scottish Medicines Consortium may issue a different recommendation than NICE for the same medicine, which can change the NHS funding picture without changing the regulatory route. Wales follows NICE for technology appraisals and supplements with AWMSG advice for medicines outside NICE scope. Northern Ireland follows NICE and SMC with attention to the Windsor Framework rules on EU medicines.

Comparison with adjacent jurisdictions

The UK Specials framework is more clinician-led and less paperwork-heavy than the equivalent named-patient pathways in the Gulf or in India. Where the UAE's EDE pathway requires a full clinical justification package with regulator pre-approval, the UK Specials route runs on the prescribing consultant's clinical judgment with notification rather than pre-authorisation for the import. The trade-off is that UK supply requires a UK-licensed wholesale dealer or Specials-licensed manufacturer in the chain, where the Gulf framework allows broader importer participation under the regulator's case-by-case approval.

Versus the United States itself, the UK relies on the consultant-led Specials route where the US uses physician-issued prescriptions against an FDA-approved drug supply, with no equivalent to the FDA's expanded access for medicines already approved for the relevant indication. The UK EAMS scheme is the closest analogue to FDA expanded access for pre-licence medicines.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator. We do not replace your consultant, do not replace the MHRA, and do not replace a UK-licensed dispensing pharmacy. What we do is orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your UK consultant and dispensing pharmacy need, coordinate validated international logistics with cold-chain monitoring where applicable, and assign a single named coordinator who runs your case from waitlist confirmation through delivery.

For UK private patients and self-funders, the value sits in the consolidation: one coordinator who understands the US manufacturer side, the international supply chain, and the UK Specials regulatory environment, rather than three separate sets of conversations across a fragmented supply chain. For UK consultants the value sits in the documentation: a complete clinical packet, a chain-of-custody plan, and a Yellow Card pharmacovigilance pathway, all configured for the Specials route.

Reserved for you.

This guide is informational, not medical or legal advice. The UK Specials framework requires a UK-licensed prescriber's clinical judgment and a UK-licensed dispensing chain; Reserve Meds is the coordinator, not the prescriber and not the UK dispensing pharmacy.

Drug-access guides for the United Kingdom

Each guide below covers the UK Specials Licence access pathway for that specific medicine, with the prescribing requirements, real GBP cost picture, dispensing route, and timing your consultant and family can expect.

Oncology and cell therapy

Gene therapy and rare disease

Neurology

Immunology and dermatology

Browse the full Reserve Meds drug catalog ›